PD204 Comparison Of Reimbursement Systems In France Denmark, Norway, And The United Kingdom - Possibilities Of Implementation In Poland

Introduction Reimbursement schemes should be regularly updated to maintain a trade-off between costs for the system and access to medicines. The aim of this study was to review reimbursement systems in several European countries in terms of solutions that could have a positive impact on the health technology assessment (HTA) and reimbursement processes in Poland (e.g., increasing patient access to medicines while maintaining payers’ spending). Methods Secondary publications and the websites of key institutions responsible for drug policy (the Ministry of Health, HTA agencies, and payers) in selected European countries were searched to find unique solutions that could have a positive impact on drug policies in Poland. The keywords used were “drug reimbursement” and “HTA”. A more specific search was conducted as needed. Results The following solutions considered worthy of further consideration: • central organization of tenders for hospital drugs and conducting price negotiations with regional financial responsibility; • determining the maximum annual copayment per patient for reimbursed drugs; • complementary private health insurance that reduces patient copayments; • creating a separate path for hybrid drugs in the HTA and pricing processes; • increasing the number of consultations with the market authorization holder, clinical experts, and the public during drug evaluation; and • not accounting for the costs of lost productivity during HTA due to the discrimination of seniors and children. Conclusions Minor changes in the HTA process, such as increasing the role of consultations, as well as major systemic changes (e.g., introducing complementary private insurance, creating a separate path for hybrid drugs, and introducing a maximum annual copayment for reimbursed drugs) could improve patients’ access to drugs. Implementing these solutions requires significant adaptation of the local legal framework.

Authors

Publication Details

Journal
International Journal of Technology Assessment in Health Care
Published
2024-12-01
DOI
https://doi.org/10.1017/s0266462324004264
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PD204 Comparison Of Reimbursement Systems In France Denmark, Norway, And The United Kingdom - Possibilities Of Implementation In Poland

Magdalena Rdzanek, Aleksandra Zawada, Magdalena Chmielewska, Marcin Dawicki
International Journal of Technology Assessment in Health Care
Health Systems, Economic Evaluations, Quality of Life
article

PD204 Comparison Of Reimbursement Systems In France Denmark, Norway, And The United Kingdom - Possibilities Of Implementation In Poland

Magdalena Rdzanek, Aleksandra Zawada, Magdalena Chmielewska, Marcin Dawicki
article en

Abstract

Introduction Reimbursement schemes should be regularly updated to maintain a trade-off between costs for the system and access to medicines. The aim of this study was to review reimbursement systems in several European countries in terms of solutions that could have a positive impact on the health technology assessment (HTA) and reimbursement processes in Poland (e.g., increasing patient access to medicines while maintaining payers’ spending). Methods Secondary publications and the websites of key institutions responsible for drug policy (the Ministry of Health, HTA agencies, and payers) in selected European countries were searched to find unique solutions that could have a positive impact on drug policies in Poland. The keywords used were “drug reimbursement” and “HTA”. A more specific search was conducted as needed. Results The following solutions considered worthy of further consideration: • central organization of tenders for hospital drugs and conducting price negotiations with regional financial responsibility; • determining the maximum annual copayment per patient for reimbursed drugs; • complementary private health insurance that reduces patient copayments; • creating a separate path for hybrid drugs in the HTA and pricing processes; • increasing the number of consultations with the market authorization holder, clinical experts, and the public during drug evaluation; and • not accounting for the costs of lost productivity during HTA due to the discrimination of seniors and children. Conclusions Minor changes in the HTA process, such as increasing the role of consultations, as well as major systemic changes (e.g., introducing complementary private insurance, creating a separate path for hybrid drugs, and introducing a maximum annual copayment for reimbursed drugs) could improve patients’ access to drugs. Implementing these solutions requires significant adaptation of the local legal framework.

International Journal of Technology Assessment in Health CareVol. 40(S1)
Peace, Justice and strong institutions
Openalex Percentile: Top 69%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.